Expert Opinion on Investigational Drugs

译名:研究性药物专家观点

EXPERT OPINION ON INVESTIGATIONAL DRUGS

SCIEJCR Q2中科院3区

3-5

2026

影响因子区间

平台估算

投稿周期

10%

2025

中国作者发文占比

£3490.00 GBP / $5090.00 USD / €3990.00 EUR.

费用说明

收费

期刊简介:Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development.The Editors welcome:Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategiesDrug Evaluations reviewing the clinical and pharmacological data on a particular drugOriginal Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trialsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

【译文】关于研究药物(ISSN 1354-3784 [印刷版],1744-7658 [电子版])是一本MEDLINE索引、同行评审的国际期刊,发表关于处于临床前和早期临床开发阶段的药物综述文章和原创论文,提供关于未来开发前景的专家意见。编辑们欢迎以下内容:涵盖特定适应症的药物或药物类别的从临床前到II期数据的综述,以及它们对未来治疗策略的潜在影响;审查特定药物的药理和临床数据的药物评估;报告处于I期和II期临床试验中药物的临床研究结果的原创研究论文。读者包括制药行业的科学家、经理和决策者,以及其他密切参与研发的人员。

出版社
Taylor & Francis
语言
English
学科
医学
ISSN
1354-3784
eISSN
1744-7658
出版频率
月刊
创刊年份
1994
投稿网址
https://mc.manuscriptcentral.com/eoid
最近更新
2026-04-02 18:16:40
Expert Opinion on Investigational Drugs

指标当前值近三年趋势
JCR分区Q2
暂无
中科院分区3区
暂无
影响因子区间3-5
暂无